Guanhao BiotechLtd Past Earnings Performance
Past criteria checks 3/6
Guanhao BiotechLtd has been growing earnings at an average annual rate of 22%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 4% per year. Guanhao BiotechLtd's return on equity is 1.6%, and it has net margins of 5.3%.
Key information
22.0%
Earnings growth rate
21.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -4.0% |
| Return on equity | 1.6% |
| Net Margin | 5.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Guanhao BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 383 | 20 | 220 | 40 |
| 31 Mar 24 | 383 | 23 | 221 | 42 |
| 31 Dec 23 | 404 | 31 | 229 | 45 |
| 30 Sep 23 | 392 | -35 | 235 | 43 |
| 30 Jun 23 | 385 | -33 | 230 | 46 |
| 31 Mar 23 | 367 | -307 | 216 | 50 |
| 01 Jan 23 | 377 | -308 | 219 | 51 |
| 30 Sep 22 | 411 | -218 | 204 | 51 |
| 30 Jun 22 | 429 | -211 | 205 | 52 |
| 31 Mar 22 | 483 | 77 | 232 | 49 |
| 01 Jan 22 | 489 | 74 | 245 | 47 |
| 30 Sep 21 | 490 | 70 | 264 | 44 |
| 30 Jun 21 | 496 | 60 | 274 | 36 |
| 31 Mar 21 | 472 | 53 | 259 | 34 |
| 31 Dec 20 | 437 | 47 | 233 | 34 |
| 30 Sep 20 | 439 | -443 | 285 | 67 |
| 30 Jun 20 | 434 | -447 | 270 | 69 |
| 31 Mar 20 | 424 | -464 | 275 | 68 |
| 31 Dec 19 | 438 | -465 | 295 | 70 |
| 30 Sep 19 | 470 | 35 | 241 | 38 |
| 30 Jun 19 | 471 | 48 | 256 | 40 |
| 31 Mar 19 | 481 | 52 | 265 | 41 |
| 31 Dec 18 | 458 | 46 | 251 | 43 |
| 30 Sep 18 | 447 | 47 | 257 | 47 |
| 30 Jun 18 | 456 | 35 | 237 | 71 |
| 31 Mar 18 | 458 | 41 | 263 | 61 |
| 31 Dec 17 | 461 | 46 | 264 | 50 |
| 30 Sep 17 | 453 | 50 | 263 | 34 |
| 30 Jun 17 | 406 | 58 | 259 | 0 |
| 31 Mar 17 | 351 | 57 | 205 | 0 |
| 31 Dec 16 | 313 | 57 | 183 | 0 |
| 30 Sep 16 | 265 | 63 | 142 | 0 |
| 30 Jun 16 | 246 | 62 | 132 | 0 |
| 31 Mar 16 | 236 | 63 | 126 | 0 |
| 31 Dec 15 | 226 | 63 | 122 | 0 |
| 30 Sep 15 | 206 | 53 | 125 | 0 |
| 30 Jun 15 | 197 | 51 | 122 | 0 |
| 10 Apr 15 | 192 | 51 | 121 | 0 |
| 31 Dec 14 | 190 | 50 | 122 | 0 |
| 30 Sep 14 | 176 | 44 | 115 | 0 |
| 30 Jun 14 | 172 | 42 | 115 | 0 |
| 31 Mar 14 | 168 | 41 | 113 | 0 |
| 31 Dec 13 | 169 | 41 | 117 | 0 |
| 30 Sep 13 | 156 | 34 | 118 | 0 |
Quality Earnings: 300238 has high quality earnings.
Growing Profit Margin: 300238 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300238 has become profitable over the past 5 years, growing earnings by 22% per year.
Accelerating Growth: 300238 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300238 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.3%).
Return on Equity
High ROE: 300238's Return on Equity (1.6%) is considered low.